Sugi Predict

Sugi Predict / Compounds / SCHEMBL708582

SCHEMBL708582

SCHEMBL708582

C[C@@H](O)[C@H](NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 9/20 0.51
▸ CTSS P25774 5/20 0.51
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CYP2D6 P10635 1/20 0.46
▸ APP P05067 1/20 0.45
▸ TSHR P16473 1/20 0.43
▸ MEN1 O00255 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CTSL P07711 2/20 0.42
▸ CTSB P07858 2/20 0.42
▸ PREP P48147 1/20 0.41
▸ TRPA1 O75762 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1312767 1.00 CTSK (0.51) CTSKCTSSCA1CA2CA7
SCHEMBL708581 1.00 CTSK (0.51) CTSKCTSSCA1CA2CA7
SCHEMBL999110 1.00 CTSK (0.51) CTSKCTSSCA1CA2CA7
SCHEMBL16710007 1.00 CTSK (0.51) CTSKCTSSCA1CA2CA7
SCHEMBL1312765 1.00 CTSK (0.51) CTSKCTSSCA1CA2CA7
SCHEMBL693616 1.00 CTSK (0.51) CTSKCTSSCA1CA2CA7
SCHEMBL1311851 1.00 CTSK (0.51) CTSKCTSSCA1CA2CA7
SCHEMBL23794778 0.89 CTSK (0.49) CTSKCTSSCA1CA2CA7
SCHEMBL30718547 0.89 CTSK (0.49) CTSKCTSSCA1CA2CA7
SCHEMBL23794776 0.89 CTSK (0.49) CTSKCTSSCA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 760 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117567552-B Four 2-Thr-tetrahydroisoquinoline-3S-formyl-AA compounds of IL-2 agonist, preparation and application 首都医科大学 2025-03-28 — — CN claimed
CN-117567553-B 2-Thr-dihydroisoquinoline-3S-formyl-AA as IL-2 agonist, and preparation and antitumor application thereof 首都医科大学 2025-03-28 — — CN claimed
CN-119118877-A Hydrophobic auxiliary material for assisting emulsification as well as synthesis method and application thereof 浙江智达药业有限公司 2024-12-13 — — CN claimed
CN-117567553-A 2-Thr-dihydroisoquinoline-3S-formyl-AA as IL-2 agonist, and preparation and antitumor application thereof 首都医科大学 2024-02-20 — — CN claimed
CN-117567552-A Four 2-Thr-tetrahydroisoquinoline-3S-formyl-AA compounds of IL-2 agonist, preparation and application 首都医科大学 2024-02-20 — — CN claimed
CN-115850137-A Pleuromutilin derivative compound and preparation method and application thereof 中国农业科学院兰州畜牧与兽药研究所 2023-03-28 — — CN claimed
CN-115252806-A Preparation method of nano-drug carrier G5-R with high-efficiency tumor penetration capacity 浙江大学杭州国际科创中心 2022-11-01 — — CN claimed
CN-109432394-B Octreotide acetate injection pharmaceutical composition and application thereof 成都天台山制药有限公司 2022-02-01 — — CN claimed
CN-101538242-B Synthetic method of Benazepril key intermediate S-amino substance UNIV ZHEJIANG TECHNOLOGY 2011-05-25 — — CN claimed
CN-101538242-A Synthetic method of Benazepril key intermediate S-amino substance UNIV ZHEJIANG TECHNOLOGY 2009-09-23 — — CN claimed
US-6951946-B2 Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates LEXICON PHARMACEUTICALS, INC. (US) 2005-10-04 — — US claimed
US-20050154211-A1 Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates KOLB HARTMUTH C (US) 2005-07-14 — — US claimed
US-20040019215-A1 Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates LEXICON PHARMACEUTICALS, INC. 2004-01-29 — — US claimed
US-6398857-B1 ACCUSTIC PIEZOELECTRIC; HOT MELT INK JET PRINTING; BENZOIC ACID VEHICLE; ALKYL OR PHENYL CARBOXYLIC ACID VISCOSITY MODIFIER; RETAINS DESIRED HARDNESS XEROX CORPORATION 2002-06-04 — — US claimed
US-6395077-B1 INKS WITH BENZOYLBENZOIC ACID AND COLORS XEROX CORPORATION 2002-05-28 — — US claimed
US-5757408-A PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING XEROX CORPORATION (US) 1998-05-26 — — US claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 — — US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 — — US claimed
EP-0667246-A1 Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds XEROX CORPORATION (US) 1995-08-16 — — EP claimed
US-4434095-A Cyclic analogue of naturally-occurring phagocytosis-stimulant peptide - threonyl-cyclo-[-N.sup.ε -lysyl-prolyl-arginyl] INSTITUTE ORGANICHESKOGO SINTEZA (SU) 1984-02-28 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154211-A1 Large scale synthesis of 1,2,4- and 1,3,4- oxadiazole carboxylates OXA1L, ODC1, CYP4B1 CTSK 2356/4885CTSS 2627/4885CA1 680/4885
US-20040019215-A1 Large scale synthesis of 1,2,4- and 1,3,4-oxadiazole carboxylates OXA1L, ODC1, CYP4B1 CTSK 2356/4885CTSS 2627/4885CA1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.